Rofecoxib Versus Ibuprofen for Acute Treatment of Migraine: a Randomised Placebo Controlled Trial U K Misra, M Jose, J Kalita

Total Page:16

File Type:pdf, Size:1020Kb

Rofecoxib Versus Ibuprofen for Acute Treatment of Migraine: a Randomised Placebo Controlled Trial U K Misra, M Jose, J Kalita 720 Postgrad Med J: first published as 10.1136/pgmj.2003.017160 on 3 December 2004. Downloaded from ORIGINAL ARTICLE Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial U K Misra, M Jose, J Kalita ............................................................................................................................... Postgrad Med J 2004;80:720–723. doi: 10.1136/pgmj.2003.012393 Background: Rofecoxib is a potent cyclo-oxygenase-2 inhibitor with a long duration of action. Its role in migraine has not been systematically evaluated. Aim: To study the efficacy of rofecoxib in migraine. Method: In a randomised placebo controlled trial rofecoxib 25 mg, ibuprofen 400 mg, and placebo were compared regarding their efficacy in relieving acute migraine attack. Migraine patients with 2–6 attacks per month were recruited. Headache severity, functional disability, and severity of associated symptoms were graded on a 0–3 scale. The primary endpoint was pain relief at two hours. Relief of associated symptoms and sustained pain relief for 24 hours were also noted. See end of article for Result: One hundred and twenty four patients were randomised into rofecoxib (42), ibuprofen (40), and authors’ affiliations placebo (42) groups. One hundred and one patients were followed up: 33 on rofecoxib, 35 ibuprofen, ....................... and 33 placebo. Patients’ ages ranged from 16–62 (mean 31.4) years, and 83 were females. Pain relief Correspondence to: at two hours was noted in 45.5% on rofecoxib, 55.6% on ibuprofen, and 9.1% in the placebo group. The Professor Usha Kant Misra, associated symptoms at two hours were reduced in 39.4% on rofecoxib, 50% on ibuprofen, and 9.1% in Department of Neurology, the placebo group. Sustained 24 hour pain relief was noted in 36.4% on rofecoxib, 41% on ibuprofen, Sanjay Gandhi PGIMS, Raebareily Road, Lucknow and 6.1% in the placebo group. In the ibuprofen group, five patients had abdominal pain but there were 226014, India; ukmisra@ no side effects in those on rofecoxib or in the control group. Both rofecoxib and ibuprofen were sgpgi.ac.in significantly effective in relieving pain, associated symptoms at two hours, and in sustained pain relief. Submitted 9 July 2003 There was no significant difference between rofecoxib and ibuprofen in aborting acute migraine attacks. Accepted 28 October 2003 Conclusions: Both ibuprofen and rofecoxib were superior to placebo in aborting an acute migraine attack, ....................... and there was no significant difference in their efficacy in an acute migraine attack. igraine is one of the commonest causes of headache, investigator (JK) and the responses were evaluated by and can be severe and last for hours to days. It is one another (MJ). The blinding was done by giving identical Mof the commonest causes of absence from work and packets containing the medication; however, the tablets were results in a considerable economic burden on society. Pre- not of identical appearance. The patients were asked to sently acetaminophen, non-steroidal anti-inflammatory drugs, maintain a headache diary and instructed to note the http://pmj.bmj.com/ ergot alkaloids, and triptans are used for treatment of an acute headache severity, functional disability, and associated sym- migraine attack. The choice of abortive treatment is based on its ptoms such as nausea, vomiting, photophobia, and phono- efficacy in relieving pain, lack of side effects, and cost. Rofecoxib phobia before and after the treatment. Severity of headache is a selective cyclo-oxygenase (COX)-2 inhibitor with good gas- and functional disability were graded on a 0–3 scale: grade trointestinal tolerance. In the treatment of arthritis rofecoxib 0 = normal, grade 1 = mild headache, grade 2 = moderate was more effective in providing symptomatic relief of pain com- headache, and grade 3 = severe headache. Similarly pared with placebo.1 Acetaminophen and celecoxib were similar functional disability was graded as 0 = normal, 1 = daily in efficacy to ibuprofen, diclofenac, naproxen, and nabume- activities mildly impaired, 2 = daily activities severely on September 30, 2021 by guest. Protected copyright. tone.2 In the available literature, we could not find a randomised impaired, and 3 = unable to perform daily activities, 4 placebo controlled trial on the efficacy of rofecoxib in migraine. requiring bed rest. Patients with grade 3 functional disability The present study, therefore, aims at evaluating the efficacy of needing bed rest during attacks and those with vomiting 20% rofecoxib and ibuprofen with placebo in the treatment of an or more of the time during a migraine attack were excluded. acute attack of migraine. The severity of associated symptoms such as nausea, vomiting, photophobia, and phonophobia were also graded on a 0–3 scale (0 = normal, 1 = mild, 2 = moderate, and 3 METHODS = severe). A detailed clinical examination was carried out in This randomised placebo controlled trial was conducted in a all the patients. The patients were randomly prescribed tertiary care teaching hospital between January 2001 and rofecoxib 25 mg, ibuprofen 400 mg, or placebo (calcium January 2002. The patients were recruited from the out- 250 mg) kept in an identical looking packet. The patients patient service of the neurology department. The protocol was were advised to take the study medication if headache was approved by the institute’s ethics committee and patients moderate or severe. Rescue medication (sumatriptan 100 mg gave consent to participate in the trial and fill in the or piroxicam 20 mg) was advised only after two hours, if headache diary. The patients had at least a 12 month history moderate or severe headache persisted (fig 1). of migraine with or without aura as defined by the criteria of Outcome was evaluated after one month or after two or more the International Headache Society.3 All the patients were attacks, which were documented in the diary. The following over 16 years of age and none had more than six attacks of three measures of efficacy were evaluated: (1) percentage of migraine per month. The patients were randomised using random number tables into three groups: rofecoxib, ibupro- Abbreviations: CI, confidence interval; COX, cyclo-oxygenase; OR, fen, and placebo. The randomisation was done by one odds ratio www.postgradmedj.com Rofecoxib v ibuprofen for treatment of migraine 721 Postgrad Med J: first published as 10.1136/pgmj.2003.017160 on 3 December 2004. Downloaded from Figure 1 Profile of randomised Registered/eligible patients (n = 124) controlled trial. Not randomised (n = 0) Reasons (n = 0) Randomisation (n = 124) Rofecoxib Ibuprofen Placebo Received standard intervention Received standard intervention Received placebo as allocated as allocated (n = 42) as allocated (n = 40) (n = 42) Did not receive standard Did not receive standard Did not receive placebo as intervention as allocated (n = 0) intervention as allocated (n = 0) allocated (n = 0) Followed up (n = 33) Followed up (n = 35) Followed up (n = 33) Timing of primary and Timing of primary and Timing of primary and secondary outcome: 2 attacks secondary outcome: 2 attacks secondary outcome: 2 attacks or 1 month or 1 month or 1 month Withdrawn (n = 0) Withdrawn (n = 1) Withdrawn (n = 0) Intervention ineffective (n = 18) Intervention ineffective (n = 16) Placbo ineffective (n = 30) Lost to follow up (n = 9) Lost to follow up (n = 6) Lost to follow up (n = 8) Other (n = 0) Other (n = 0) Other (n = 0) Completed trial (n = 33) Completed trial (n = 35) Completed trial (n = 33) patients with pain relief at two hours, (2) percentage of patients 99% of the patients. Vomiting in these patients, however, did free of associated symptoms—that is, absence of nausea, vomit- not exceed 20% of the time of the migraine attack. ing, photophobia, or phonophobia, and (3) percentage of patients with 24 hours of sustained pain relief—that is, absence Efficacy analysis of recurrence of headache and lack of requirement of antimi- In the 101 patients included in this study, active drugs more graine medication for 24 hours. Headache recurrence was frequently aborted the migraine attack compared with defined as the recurrence of moderate to severe headache placebo at two hours. In the rofecoxib group 45.5% of the within 24 hours of dosing in patients who initially had relief of patients were relieved of pain and 39.4% were free of pain two hours after medication. Any side effects of the drugs associated symptoms at two hours. In the ibuprofen group up to 24 hours after ingestion were also noted. 55.6% patients were relieved of pain and 50% were free of http://pmj.bmj.com/ This study was designed as a non-inferiority trial expecting associated symptoms, while in the placebo group it was 9.1% rofecoxib to be as good as ibuprofen and superior to placebo. for both measures. In the rofecoxib group, sustained pain In order to detect the difference between the two drugs alpha relief was present in 36.4% patients, in the ibuprofen group risk was taken as 5%, critical difference in the drugs was 41.7%, and in control group only 6.1%. Two hour pain relief taken as 10%, and the power calculation was done according 5 was significantly superior in rofecoxib (odds ratio (OR) 8.33, to the method described by Agresti. Sample size was based 95% confidence interval (CI) 2.12 to 32.65, power 0.83) and on the response rate. Pain relief at two hours was considered ibuprofen (OR 12.50, 95% CI 3.22 to 48.55, power 0.82) on September 30, 2021 by guest. Protected copyright. important (efficacy of the drug) and the standard deviation compared with placebo. In relieving associated symptoms ¡ was taken as 2. Based on this criterion the sample size was rofecoxib (OR 6.5, 95% CI 1.64 to 25.76, power 0.83) and calculated to be at least 30 in each group.
Recommended publications
  • Studies on the Cardiovascular Effects of Selective COX-2 Inhibitors Show Mixed Results
    Review: studies on the cardiovascular effects of Evid Based Med: first published as 10.1136/ebm.7.2.49 on 1 March 2002. Downloaded from selective COX-2 inhibitors show mixed results Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 Aug 22/29;286:954–9. QUESTION: In patients with arthritis, do rofecoxib or celecoxib increase the risk for cardiovascular events? Data sources increase 138%, 95% CI 39 to 300; number needed to Studies were identified by searching Medline (1998 to harm 146, CI 69 to 517}*. The Celecoxib Long-term February 2001) and the internet. The Adverse Events Arthritis Safety Study (CLASS) compared celecoxib 400 Reporting System was searched for US events on Octo- mg twice daily; ibuprofen 800 mg 3 times daily; and ber 12, 2000. diclofenac 75 mg twice daily, in 8059 patients with osteoarthritis or rheumatoid arthritis. Patients were Study selection allowed to take aspirin ( < 325 mg/day). Celecoxib and English language studies were selected if they were ran- non-steroidal anti-inflammatory drugs did not differ for domised, double blind, controlled trials reporting the cardiovascular event rates. 2 studies compared rofecoxib cardiovascular effects of celecoxib or rofecoxib. 12.5 mg/day; nabumetone 1000 mg/day; and placebo for 6 weeks in 1042 and 978 patients with osteoarthritis Data extraction of the knee. Patients were allowed to take low dose aspi- Data were extracted on study methods, patient charac- rin. In both studies, the groups did not differ for cardio- teristics, drug regimens, aspirin use, and cardiovascular vascular event rates.
    [Show full text]
  • Nonsteroidal Antiinflammatory Drugs Inhibiting Prostanoid Efflux: As Easy As ABC?
    Nonsteroidal antiinflammatory drugs inhibiting prostanoid efflux: As easy as ABC? Timothy D. Warner*† and Jane A. Mitchell‡ *The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, United Kingdom; and ‡National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, United Kingdom onsteroidal antiinflammatory may explain its antinociceptive proper- resistance proteins (MRP) form a sub- drugs (NSAIDs) and prosta- ties (7). Others have found therapeutic family within the ABC transporters. noids continue to be fascinat- effects of NSAID metabolites that are MRP1 is a high-affinity leukotriene C4 N ing research targets. Humans inactive on COX; sulindac sulfone is a transporter, and mice that harbor dele- have been using NSAIDs in one form or clear example. The NSAID sulindac is tions of this gene have an altered re- another, from folk remedies through to an inactive drug metabolized to a phar- sponse to inflammatory stimuli but are the products of modern pharmaceutical macologically active sulfide derivative, otherwise healthy and fertile. MRP2 is research, for thousands of years. How- which potently inhibits COX. Sulindac is the major transporter responsible for ever, we still have not characterized all also metabolized to a sulfone derivative the secretion of bilirubin glucuronides of the systems through which these that is inactive against COX. However, into bile (11). MRP1 and -4 may also be drugs produce their beneficial and like sulindac sulfide, sulindac sulfone involved in the transport of dehydroepi- harmful effects (1, 2). We are certain, both promotes cellular apoptosis and androsterone 3-sulfate (the most abun- from seminal work carried out in the dant circulating steroid in humans), and 1960s and early 1970s, that NSAIDs MRP4 transports conjugated steroids have the common property of inhibiting Some NSAIDs and bile acids (12).
    [Show full text]
  • Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: a Systematic Review
    J Pharm Pharm Sci (www.cspsCanada.org) 21, 48s – 73s, 2018 Clinical Outcomes of Aspirin Interaction with Other Non-Steroidal Anti- Inflammatory Drugs: A Systematic Review Zuhair Alqahtani and Fakhreddin Jamali Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Alberta, Canada. Received, March 16, 2018; Revised, March 30, 2018; Accepted, April 25, 2018; Published, April 27, 2018. ABSTRACT - Purpose: Concomitant use of some non-Aspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) reduces the extent of platelet aggregation of Aspirin (acetylsalicylic acid). This is while many observational studies and clinical trials suggest that Aspirin reduces cardiovascular (CV) risk attributed to the use of NANSAIDs. Thus, the therapeutic outcome of the interaction needs to be assessed. Methods: We searched various databases up to October 2017 for molecular interaction studies between the drugs and long-term clinical outcomes based on randomized clinical trials and epidemiological observations that reported the effect estimates of CV risks (OR, RR or HR; 95% CI) of the interacting drugs alone or in combinations. Comparisons were made between outcomes after Aspirin alone, NANSAIDs alone and Aspirin with naproxen, ibuprofen, celecoxib, meloxicam, diclofenac or rofecoxib. Results: In total, 32 eligible studies (20 molecular interactions studies and 12 observational trials) were found. Conflicting in vitro/in vivo/ex vivo platelet aggregation data were found for ibuprofen, naproxen and celecoxib. Nevertheless, for naproxen, the interaction at the aggregation level did not amount to a loss of cardioprotective effects of Aspirin. Similarly, for ibuprofen, the results overwhelmingly suggest no negative clinical CV outcomes following the combination therapy. Meloxicam and rofecoxib neither interacted with Aspirin at the level of platelet aggregation nor altered clinical outcomes.
    [Show full text]
  • VIOXX® (Rofecoxib Tablets and Oral Suspension)
    VIOXX® (rofecoxib tablets and oral suspension) WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS). VIOXX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS, WARNINGS). Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. (see WARNINGS). DESCRIPTION VIOXX® (rofecoxib) is a nonsteroidal anti-inflammatory drug (NSAID). The chemical name is 4-[4­ (methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone. The molecular weight is 314.36. The empirical formula for rofecoxib is C17H14O4S, and it has the following chemical structure: O O O S H C 3 O Rofecoxib is a white to off-white to light yellow powder. It is sparingly soluble in acetone, slightly soluble in methanol and isopropyl acetate, very slightly soluble in ethanol, practically insoluble in octanol, and insoluble in water. Each tablet of VIOXX for oral administration contains either 12.5 mg, 25 mg, or 50 mg of rofecoxib and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, and yellow ferric oxide.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Metabolic Profiling of Murine Plasma Reveals an Unexpected Biomarker In
    Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events Jun-Yan Liua, Ning Lib, Jun Yanga, Nan Lic, Hong Qiub, Ding Aia,c, Nipavan Chiamvimonvatb, Yi Zhuc, and Bruce D. Hammocka,1 aDepartment of Entomology and University of California-Davis Cancer Center and bDivision of Cardiovascular Medicine, University of California, Davis, CA 95616; and cDepartment of Physiology, Beijing University, Beijing 100083, People’s Republic of China Contributed by Bruce D. Hammock, August 6, 2010 (sent for review June 16, 2010) Chronic administration of high levels of selective COX-2 inhibitors infarction (MI), hypertension, and heart failure has also been ob- (coxibs), particularly rofecoxib, valdecoxib, and parecoxib, increases served to be associated with the administration of the nonaspirin risk for cardiovascular disease. Understanding the possibly multiple conventional NSAIDs, including but not limited to diclofenac, mechanisms underlying these adverse cardiovascular events is critical ibuprofen, naproxen, and indomethacin (8–12). In addition, there for evaluating the risks and benefits of coxibs and for development of could be rofecoxib-specific events such as the facile formation of safer coxibs. The current understanding of these mechanisms is likely a cardiotoxic maleic anhydride derivative from rofecoxib that may incomplete. Using a metabolomics approach, we demonstrate that contribute to its adverse effects (13). This hypothesis fails to ex- oral administration of rofecoxib for 3 mo results in a greater than 120- plain the increased risk in the cardiovascular system from other fold higher blood level of 20-hydroxyeicosatetraenoic acid (20-HETE), nonaspirin NSAIDs. Thus, current mechanisms provide an in- fi which correlates with a signi cantly shorter tail bleeding time in complete explanation for cardiovascular problems associated with a murine model.
    [Show full text]
  • Aspirin and Other Anti-Inflammatory Drugs
    Thorax 2000;55 (Suppl 2):S3–S9 S3 Aspirin and other anti-inflammatory drugs Thorax: first published as 10.1136/thorax.55.suppl_2.S3 on 1 October 2000. Downloaded from Sir John Vane Historical introduction inhibiting COX, thereby reducing prosta- Salicylic acid, the active substance in plants glandin formation, providing a unifying expla- used for thousands of years as medicaments, nation for their therapeutic actions and their was synthesised by Kolbe in Germany in 1874. side eVects. This also firmly established certain MacLagan1 and Stricker2 showed that it was prostaglandins as important mediators of eVective in rheumatic fever. A few years later inflammatory disease (see reviews by Vane and sodium salicylate was also in use as a treatment Botting7 and Vane et al8). COX first cyclises for chronic rheumatoid arthritis and gout as arachidonic acid to form prostaglandin (PG) well as an antiseptic compound. G2 and the peroxidase part of the enzyme then Felix HoVman was a young chemist working reduces PGG2 to PGH2. at Bayer. Legend has it that his father, who was taking salicylic acid to treat his arthritis, Discovery of COX-2 complained to his son about its bitter taste. Over the next 20 years several groups postu- Felix responded by adding an acetyl group to lated the existence of isoforms of COX. Then salicylic acid to make acetylsalicylic acid. Rosen et al,9 studying COX in epithelial cells Heinrich Dreser, the Company’s head of phar- from the trachea, found an increase in activity macology, showed it to be analgesic, anti- of COX during prolonged cell culture.
    [Show full text]
  • Ketorolac Tromethamine Injection, USP
    PRODUCT MONOGRAPH Pr Ketorolac Tromethamine Injection, USP 30 mg / mL single-dose vials 30 mg / mL in SimplistTM prefilled single use syringes For Intramuscular Administration Non-Steroidal Anti-Inflammatory Analgesic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 July 18, 2019 Toronto, ON M9W 0C8 Submission Control No.: 227928 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ................................................................................3 INDICATIONS AND CLINICAL USE .....................................................................................3 CONTRAINDICATIONS ...........................................................................................................4 WARNINGS AND PRECAUTIONS .........................................................................................5 ADVERSE REACTIONS .........................................................................................................14 DRUG INTERACTIONS..........................................................................................................16 DOSAGE AND ADMINISTRATION .....................................................................................18 OVERDOSAGE ........................................................................................................................22 ACTION AND CLINICAL PHARMACOLOGY ....................................................................23 STORAGE
    [Show full text]
  • Acute Congestive Heart Failure Induced by Rofecoxib
    J Am Board Fam Pract: first published as 10.3122/jabfm.17.2.131 on 13 April 2004. Downloaded from Acute Congestive Heart Failure Induced by Rofecoxib Robert J. Campbell, MD, and Kevin B. Sneed, PharmD Nonsteroidal anti-inflammatory drugs (NSAIDs) COX-1 in the stomach is believed to have protec- are routinely prescribed for the treatment of vari- tive properties of the gastric mucosa.12,13 COX-2 is ous conditions requiring analgesia and anti-inflam- expressed in response to inflammatory stimuli, and matory activity. People also have access to NSAIDs is affected by cytokines and other inflammatory over-the-counter for relief of mild aches, pains, and mediators. Most NSAIDs inhibit both isoforms to headaches. NSAIDs have the potential to produce varying degrees, relative to the activity of the indi- several adverse effects in patients. They are known vidual chemical properties of the NSAID. In recent to have the potential to produce gastrointestinal years, COX-2 specific inhibitors have become toxicities leading to dyspepsia or even ulceration. available [celecoxib, rofecoxib, valdecoxib (in order Gastrointestinal symptoms are the most common of US market release)]. It had been hypothesized adverse effects associated with NSAID use.1 Plate- that by targeting the COX-2 enzyme specifically, let aggregation is known to be inhibited by only the inflammatory prostaglandins would be in- NSAIDs because of their ability to inhibit the ac- hibited while sparing the activity of COX-1. This tion of thromboxane A, a potent platelet aggrega- would allow the medication to produce anti- tor.2–4 This could lead to hemorrhaging in patients inflammatory and analgesia activities without po- with vascular injuries or congenital hematologic tentially decreasing the protective effects of the conditions.
    [Show full text]
  • Ketorolac Tromethamine Injection Usp
    PRODUCT MONOGRAPH PrKETOROLAC TROMETHAMINE INJECTION USP (Ketorolac Tromethamine) Sterile Solution 30 mg/mL Non-Steroidal Anti-Inflammatory Drug (NSAID) Pfizer Canada Inc. Date of Revision: 17300 Trans-Canada Highway December 1, 2017 Kirkland, Québec H9J 2M5 Submission Control No: 209949 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................14 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................19 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • COX-2 Selective Non-Steroidal Anti-Inflammatory Drugs For
    Health Technology Assessment Health Technology Health Technology Assessment 2008; Vol. 12: No. 11 2008; 12: No. 11 Vol. selective non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis COX-2 Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation Feedback The HTA Programme and the authors would like to know Y-F Chen, P Jobanputra, P Barton, S Bryan, your views about this report. The Correspondence Page on the HTA website A Fry-Smith, G Harris and RS Taylor (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. April 2008 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.
    [Show full text]
  • Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Patients with Osteoarthritis of the Knee. a Combined Analysis of the VACT Studies THOMAS J
    Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Patients with Osteoarthritis of the Knee. A Combined Analysis of the VACT Studies THOMAS J. SCHNITZER, ARTHUR L. WEAVER, ADAM B. POLIS, RICHARD A. PETRUSCHKE, and GREGORY P. GEBA, for the VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups ABSTRACT. Objective. To compare efficacy among 1578 patients with osteoarthritis randomized to take aceta- minophen 4000 mg (n = 269), celecoxib 200 mg (n = 523), rofecoxib 12.5 mg (n = 259), or rofe- coxib 25 mg (n = 527) in a double blind trial [Vioxx, Acetaminophen, Celecoxib Trial (VACT2)]. Results were also pooled with the similarly designed VACT1 trial. Methods. Patients evaluated over Days 1 to 6 and 6 weeks with Patient Global Assessment of Response to Therapy (PGART) and Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Results. For VACT2, median time to good or excellent PGART response was 6, 5, 4, and 3 days for acetaminophen, celecoxib, rofecoxib 12.5 mg, and rofecoxib 25 mg (COX-2 inhibitors vs acetamin- ophen, p ≤ 0.035; rofecoxib 25 mg vs celecoxib, p = 0.01). WOMAC response over the first 6 days was greater (p < 0.05) with both rofecoxib doses than acetaminophen and celecoxib. At Week 6, all COX-2 inhibitors provided significantly greater efficacy than acetaminophen. Good or excellent PGART was numerically, but not significantly, greater with rofecoxib 25 mg (55.4%) than celecox- ib (50.6%) at Week 6; a significant difference was seen at Weeks 2 (6.9, p = 0.022) and 4 (6.7, p = 0.027) and over 6 weeks with analysis of all 5 PGART categories of response (p = 0.035).
    [Show full text]